DexCom Inc. (D1EX34 SA) stock market data APIs
R$8.7876
0.1(1.1%)
as of October 30, 2026
Try our APIs with
free plan!
DexCom Inc. Financial Data Overview
Price chart is built with
Anychart
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Prev. Close
8.7876
Open
8.8874
High
9.1793
Low
8.7842
52 wk Range
5.75-9.57
Market Cap
162 420 M
P/E Ratio
32.2593
Shares Outstanding
18 648 M
Revenue
5 104 M
Beta
1.477
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get DexCom Inc. data using free add-ons & libraries
Get DexCom Inc. Fundamental Data
DexCom Inc. Fundamental data includes:
- Net Revenue: 5 104 M
- EBITDA: 1 491 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DexCom Inc. News
New
DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory
DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street's expectations in Q3 2026, wi...
DexCom (DXCM) Stock Looks Below Fair Value on Cash Flow
DexCom has enjoyed a strong run over the past year, yet the share price still leaves a basic question on the table for investors who care about cash flows. With the stock now trading around US$82.29, ...
DexCom (DXCM) Brings Its 15 Day Glucose Monitor To Canada
DexCom (NasdaqGS:DXCM) has launched its Dexcom G7 15 Day Continuous Glucose Monitoring System in Canada, following Health Canada authorization. The Dexcom G7 15 Day is described as the longest duratio...
DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says
DexCom (DXCM) posted better-than-expected Q3 results and raised its 2026 revenue guidance, and US sh Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news ...
Get DexCom Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.